Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019

Le Chang; Lei Zhao; Yan Xiao; Tingting Xu; Lan Chen; Yan Cai; Xiaojing Dong; Conghui Wang; Xia Xiao; Lili Ren; Lunan Wang

doi:10.1093/procel/pwac013

Volume 14 Issue 1

Jan. 2023

Turn off MathJax

Article Contents

Article Navigation > Protein&Cell > 2023 > 14(1): 28-36

Le Chang, Lei Zhao, Yan Xiao, Tingting Xu, Lan Chen, Yan Cai, Xiaojing Dong, Conghui Wang, Xia Xiao, Lili Ren, Lunan Wang. Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019[J]. Protein&Cell, 2023, 14(1): 28-36. doi: 10.1093/procel/pwac013

Citation:

Le Chang, Lei Zhao, Yan Xiao, Tingting Xu, Lan Chen, Yan Cai, Xiaojing Dong, Conghui Wang, Xia Xiao, Lili Ren, Lunan Wang. Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019[J]. Protein&Cell, 2023, 14(1): 28-36. doi: 10.1093/procel/pwac013

Citation:

Le Chang, Lei Zhao, Yan Xiao, Tingting Xu, Lan Chen, Yan Cai, Xiaojing Dong, Conghui Wang, Xia Xiao, Lili Ren, Lunan Wang. Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019[J]. Protein&Cell, 2023, 14(1): 28-36. doi: 10.1093/procel/pwac013

PDF( 652 KB)

Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019

doi: 10.1093/procel/pwac013

Le Chang^1,2,
Lei Zhao^3,4,
Yan Xiao^5,6,
Tingting Xu^3,4,
Lan Chen^5,6,
Yan Cai⁷,
Xiaojing Dong^5,6,
Conghui Wang^5,6,
Xia Xiao^5,6,
Lili Ren^{5,6
,
,},
Lunan Wang^{1,2,8
,
,}

1 National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China;
2 Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing 100730, China;
3 Department of Laboratory, Wuhan Blood Center, Wuhan 430030, China;
4 Confirmation Laboratory for Transfusion Transmitted Disease, Institute of Blood Transfusion of Hubei Province, Wuhan 430030, China;
5 National Health Commission of the People's Republic of China Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China;
6 Key Laboratory of Respiratory Disease Pathogenomics, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China;
7 Department of Quality Control, Wuhan Blood Center, Wuhan 430030, China;
8 Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China

Funds:

This work was supported by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-1-038).

Received Date: 2022-04-26
Rev Recd Date: 2022-05-09
Publish Date: 2023-01-01

Abstract

Abstract

The emerging of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused COVID-19 pandemic. The first case of COVID-19 was reported at early December in 2019 in Wuhan City, China. To examine specific antibodies against SARS-CoV-2 in biological samples before December 2019 would give clues when the epidemic of SARS-CoV-2 might start to circulate in populations. We obtained all 88,517 plasmas from 76,844 blood donors in Wuhan between 1 September and 31 December 2019. We first evaluated the pan-immunoglobin (pan-Ig) against SARS-CoV-2 in 43,850 samples from 32,484 blood donors with suitable sample quality and enough volume. Two hundred and sixty-four samples from 213 donors were pan-Ig reactive, then further tested IgG and IgM, and validated by neutralizing antibodies against SARS-CoV-2. Two hundred and thirteen samples (from 175 donors) were only pan-Ig reactive, 8 (from 4 donors) were pan-Ig and IgG reactive, and 43 (from 34 donors) were pan-Ig and IgM reactive. Microneutralization assay showed all negative results. In addition, 213 screened reactive donors were analyzed and did not show obviously temporal or regional tendency, but the distribution of age showed a difference compared with all tested donors. Then we reviewed SARS-CoV-2 antibody results from these donors who donated several times from September 2019 to June 2020, partly tested in a previous published study, no one was found a significant increase in S/CO of antibodies against SARS-CoV-2. Our findings showed no SARS-CoV-2-specific antibodies existing among blood donors in Wuhan, China before 2020, indicating no evidence of transmission of COVID-19 before December 2019 in Wuhan, China.
- severe acute respiratory syndrome coronavirus 2,
- coronavirus disease 2019,
- seroprevalence,
- neutralizing antibodies,
- blood donors

FullText(HTML)

References(33)

References

[1]	Apolone G, Montomoli E, Manenti A et al. Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy.Tumori 2021;107:446–51.
[2]	Atsma F, Veldhuizen I, Verbeek A et al. Healthy donor effect: its magnitude in health research among blood donors. Transfusion 2011;51:1820–8.
[3]	Bao L, Deng W, Huang B et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 2020;583:830–3.
[4]	Basavaraju SV, Patton ME, Grimm K et al. Serologic testing of US blood donations to identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-reactive antibodies: December 2019–January 2020. Clin Infect Dis 2021;72:e1004–9.
[5]	Bayona-Pacheco B, Acosta-Reyes J, Navarro E et al. Seroprevalence of Zika virus among blood donors before the epidemic in Barranquilla, Colombia, 2015–2016. An Acad Bras Cienc 2019;91:e20180860.
[6]	Busch MP, Stone M. Serosurveillance for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) incidence using global blood donor populations. Clin Infect Dis 2021;72:254–6.
[7]	Butler D, Coyne D, Pomeroy L et al. Confirmed circulation of SARSCoV-2 in Irish blood donors prior to first national notification of infection. J Clin Virol 2022;146:105045.
[8]	Chang L, Hou W, Zhao L et al. The prevalence of antibodies to SARSCoV-2 among blood donors in China. Nat Commun 2021;12:1383.
[9]	Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg 1952;46:509–20.
[10]	Erikstrup C, Hother CE, Pedersen OBV et al. Estimation of SARSCoV-2 infection fatality rate by real-time antibody screening of blood donors. Clin Infect Dis 2021;72:249–53.
[11]	Fongaro G, Stoco PH, Souza DSM et al. The presence of SARS-CoV-2 RNA in human sewage in Santa Catarina, Brazil, November 2019. Sci Total Environ 2021;778:146198.
[12]	GeurtsvanKessel CH, Okba NMA, Igloi Z et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat Commun 2020;11:3436.
[13]	Gudbjartsson DF, Norddahl GL, Melsted P et al. Humoral immune response to SARS-CoV-2 in Iceland.N Engl J Med2020;383:1724–34.
[14]	He Z, Ren L, Yang J et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China:a longitudinal, population-level, cross-sectional study. Lancet 2021;397:1075–84.
[15]	Kong WH, Li Y, Peng MW et al. SARS-CoV-2 detection in patients with influenza-like illness. Nat Microbiol 2020;5:675–8.
[16]	Lassaunière R, Frische A, Harboe ZBet al. Evaluation of nine commercial SARS-CoV-2 immunoassays. medRxiv, 2020, 2020.04.09.20056325, preprint: not peer reviewed. doi: 10.1101/2020.04.09.20056325
[17]	Li Q, Guan X, Wu P et al. Early transmission dynamics in Wuhan, China, of Novel Coronavirus-infected pneumonia. N Engl J Med 2020;382:1199–207.
[18]	Lou B, Li TD, Zheng SF et al. Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset. Eur Respir J 2020;56:2000763.
[19]	Lustig Y, Keler S, Kolodny R et al. Potential antigenic cross-reactivity between Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2) and Dengue Viruses.Clin Infect Dis 2021;73:e2444–9.
[20]	Lv H, Wu NC, Tsang OT et al. Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. Cell Rep 2020;31:107725.
[21]	Mateus J, Grifoni A, Tarke A et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science 2020;370:89–94.
[22]	Pinto D, Park YJ, Beltramello M et al. Cross-neutralization of SARSCoV-2 by a human monoclonal SARS-CoV antibody. Nature 2020;583:290–5.
[23]	Post N, Eddy D, Huntley C et al. Antibody response to SARSCoV-2 infection in humans: a systematic review. PLoS One 2020;15:e0244126.
[24]	Reed LD, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938;27:493–7.
[25]	Ren L, Fan G, Wu W et al. Antibody responses and clinical outcomes in adults hospitalized with severe coronavirus disease 2019(COVID-19): a post hoc analysis of LOTUS China trial. Clin Infect Dis 2021;72:e545–51.
[26]	Ren LL, Wang YM, Wu ZQ et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl) 2020;133:1015–24.
[27]	Slavov SN, Guaragna Machado RR, Ferreira AR et al. Zika virus seroprevalence in blood donors from the Northeastern region of Sao Paulo State, Brazil, between 2015 and 2017. J Infect 2020;80:111–5.
[28]	Wang Q, Chen H, Shi Y et al. Tracing the origins of SARS-CoV-2: lessons learned from the past. Cell Res 2021;31:1139–41.
[29]	World Health Organization. WHO-convened Global Study of Origins of SARS-CoV-2: China part. 2021.
[30]	Wu Z, Jin Q, Wu G et al. SARS-CoV-2’s origin should be investigated worldwide for pandemic prevention. Lancet 2021;398:1299–303.
[31]	Yuan M, Wu NC, Zhu X. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 2020;368:630–3.
[32]	Zhao J, Yuan Q, Wang H et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis 2020;71:2027–34.
[33]	Zhu N, Zhang D, Wang W et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33.